Evidence map›Paper›PMID 38549745›Full record

ArticleFrontiers in nutrition2024

Development of celiac-safe foods: prevention of transglutaminase 2 (TG2) deamidation of gluten in healthy non-celiac volunteers.

Niklas Engström, Lena Böhn, Axel Josefsson, Stine Störsrud, Nathalie Scheers

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in nutrition, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06005376 (Development of a Celiac Safe Food Additive), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06005376 nacompletednot on this map

Development of a Celiac Safe Food Additive: An Intervention Study in Healthy Volunteers

TypeinterventionalSponsorChalmers University of TechnologyRan2020 to 2020Enrolled20ConditionsGluten IntoleranceArmsBreakfast rolls consisting of wheat flour with and without a E304i/zinc additive
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Niklas EngströmDepartment of Life Sciences, Chalmers University of Technology, Gothenburg, Sweden.
Lena BöhnDepartment of Life Sciences, Chalmers University of Technology, Gothenburg, Sweden.
Axel JosefssonDepartment of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Stine StörsrudDepartment of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Nathalie ScheersDepartment of Life Sciences, Chalmers University of Technology, Gothenburg, Sweden.
University of Gothenburg · SEChalmers University of Technology · SELund University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In celiac disease, intestinal transglutaminase (TG2) produces immunogenic peptides by deamidation of gluten proteins. These products drive the celiac immune response. We have previously identified an interaction between gliadin and a food additive, E304i, which prevents gliadin processing (both deamidation and transamidation) by TG2, Clinical trial registration: clinicaltrials.gov, identifier (NCT06005376).

Indexed as

ascorbyl palmitateceliacdeamidationDGDPglutentransglutaminase 2

Identifiers

PMID38549745
PMCPMC10972847
OpenAlexW4392814358

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.